After hours: March 14 at 7:23:43 PM EDT Loading Chart for HALO ...

Halozyme Therapeutics, Inc. is headquartered in San Diego, CA. The company has a somewhat unique business model as it uses its proprietary ENHANZE drug delivery platform to improve or "enhance ...

SAN DIEGO, Feb. 26, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host ...

Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. The firm had revenue of $298.01 million for the quarter, compared to analysts’ expectations of $285.74 million.

US biotech Halozyme Therapeutics has withdrawn its offer to acquire Evotec, saying that the German company had been "unwilling to engage with us to explore a potential combination." Halozyme made ...

Throughout the last three months, 9 analysts have evaluated Halozyme Therapeutics HALO, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Halozyme delivered a record-breaking 2024, surpassing $1 billion in revenue and setting the stage for strong growth in 2025, driven by key products like DARZALEX subcutaneous and VYVGART Hytrulo.